Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kent W Mouw, M.D., Ph.D.


Available: 11/02/20, Expires: 07/01/22

My laboratory uses genomic and functional approaches to study the determinants of response to existing and emerging therapies for prostate and bladder cancer.

The student's role would be to lead a project investigating the impact of specific clinically observed gene mutations on tumor biology and treatment response using cell and molecular biology techniques as well as genomic analyses. Experience with cell culture, sterile technique, and molecular biology techniques is encouraged but not required. The project would be conducted in my laboratory in the HIM building and the student would work directly with me to develop experiments, interpret results, and present findings.

The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. K08CA219504 (MOUW, KENT W) Aug 1, 2017 - Jul 31, 2022
    Investigating the effect of ERCC2 mutations on DNA repair capacity and chemo-radiotherapy response in muscle-invasive bladder cancer
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Dee EC, Mahal BA, Arega MA, D'Amico AV, Mouw KW, Nguyen PL, Muralidhar V. Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. JAMA Oncol. 2020 10 01; 6(10):1630-1632. PMID: 32789489.
    Citations:    Fields:    
  2. Van Hemelrijck M, Patel P, Mouw KW. Editorial: Bladder Cancer - A Cinderella Cancer: Advances and Remaining Research Questions. Front Oncol. 2020; 10:1749. PMID: 33014863.
  3. Bellmunt J, Kim J, Reardon B, Perera-Bel J, Orsola A, Rodriguez-Vida A, Wankowicz SA, Bowden M, Barletta JA, Morote J, de Torres I, Juanpere N, Lloreta-Trull J, Hernandez S, Mouw KW, Taplin ME, Cejas P, Long HW, Van Allen EM, Getz G, Kwiatkowski DJ. Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer. Cancer Res. 2020 Oct 15; 80(20):4476-4486. PMID: 32868381.
    Citations:    Fields:    
  4. Chipidza FE, Alshalalfa M, Mahal BA, Karnes RJ, Liu Y, Davicioni E, Martin NE, Mouw KW, Feng FY, Nguyen PL, Muralidhar V. Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clin Genitourin Cancer. 2020 Aug 13. PMID: 32896505.
    Citations:    Fields:    
  5. Lamba N, Butler S, Mahal BA, Trinh QD, Rose B, King M, Orio P, Mouw KW, Martin N, Leeman JE, Feng FY, Nguyen PL, Muralidhar V. Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-making. Urology. 2020 Nov; 145:197-203. PMID: 32763323.
    Citations:    Fields:    
  6. Yang DD, Muralidhar V, Mahal BA, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Martin NE, King MT, Mouw KW, Choueiri TK, Trinh QD, Nguyen PL, Orio PF. Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urol Oncol. 2020 Sep; 38(9):735.e9-735.e15. PMID: 32654951.
    Citations:    Fields:    
  7. Tabrizi S, Alshalalfa M, Mahal BA, Davicioni E, Liu Y, Mouw KW, Feng F, Nguyen PL, Muralidhar V. Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. Int J Radiat Oncol Biol Phys. 2020 Nov 15; 108(4):936-940. PMID: 32585335.
    Citations:    Fields:    
  8. Koyen AE, Madden MZ, Park D, Minten EV, Kapoor-Vazirani P, Werner E, Pfister NT, Haji-Seyed-Javadi R, Zhang H, Xu J, Deng N, Duong DM, Pecen TJ, Frazier Z, Nagel ZD, Lazaro JB, Mouw KW, Seyfried NT, Moreno CS, Owonikoko TK, Deng X, Yu DS. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair. Oncogene. 2020 06; 39(25):4798-4813. PMID: 32457468.
    Citations:    Fields:    
  9. de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, Miyamoto DT, Lotan Y, Black PC, Gibb EA, Porten SP. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. Eur Urol Oncol. 2020 08; 3(4):420-423. PMID: 32205136.
    Citations: 1     Fields:    
  10. Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, Ricker C, Kochupurakkal BS, Choudhury AD, Hahn WC, Balk SP, Hwang JH, Van Allen EM, Mouw KW. ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res. 2020 06 01; 80(11):2094-2100. PMID: 32127357.
    Citations: 1     Fields:    
  11. Butler SS, Dee EC, Lamba N, Sha ST, Mahal BA, Whitbeck A, Makkar R, Wangoe J, Mouw KW, Nguyen PL, Muralidhar V. Validation of a subclassification for high-risk prostate cancer in a prospective cohort. Cancer. 2020 May 15; 126(10):2132-2138. PMID: 32073662.
    Citations: 1     Fields:    
  12. Nassar AH, Mouw KW, Jegede O, Shinagare AB, Kim J, Liu CJ, Pomerantz M, Harshman LC, Van Allen EM, Wei XX, McGregor B, Choudhury AD, Preston MA, Dong F, Signoretti S, Lindeman NI, Bellmunt J, Choueiri TK, Sonpavde G, Kwiatkowski DJ. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. Br J Cancer. 2020 02; 122(4):555-563. PMID: 31857723.
    Citations: 3     Fields:    
  13. Nassar AH, Abou Alaiwi S, AlDubayan SH, Moore N, Mouw KW, Kwiatkowski DJ, Choueiri TK, Curran C, Berchuck JE, Harshman LC, Nuzzo PV, Chanza NM, Van Allen E, Esplin ED, Yang S, Callis T, Garber JE, Rana HQ, Sonpavde G. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet Med. 2020 04; 22(4):709-718. PMID: 31844177.
    Citations:    Fields:    
  14. Rajkumar-Calkins AS, Szalat R, Dreze M, Khan I, Frazier Z, Reznichenkov E, Schnorenberg MR, Tsai YF, Nguyen H, Kochupurakkal B, D'Andrea AD, Shapiro GI, Lazaro JB, Mouw KW. Functional profiling of nucleotide Excision repair in breast cancer. DNA Repair (Amst). 2019 10; 82:102697. PMID: 31499327.
    Citations: 1     Fields:    Translation:HumansCells
  15. Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw. 2019 08 01; 17(8):941-948. PMID: 31390585.
    Citations:    Fields:    Translation:Humans
  16. Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL. Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019 11 01; 105(3):621-627. PMID: 31271825.
    Citations:    Fields:    Translation:Humans
  17. Butler SS, Mahal BA, Lamba N, Mossanen M, Martin NE, Mouw KW, Nguyen PL, Muralidhar V. Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. Cancer. 2019 09 15; 125(18):3164-3171. PMID: 31150125.
    Citations: 2     Fields:    Translation:Humans
  18. Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA. Active Surveillance for Low-Risk Prostate Cancer in Black Patients. N Engl J Med. 2019 05 23; 380(21):2070-2072. PMID: 31116925.
    Citations: 3     Fields:    Translation:Humans
  19. Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clin Cancer Res. 2019 07 01; 25(13):3908-3920. PMID: 30952638.
    Citations: 4     Fields:    Translation:HumansCells
  20. Mouw KW, Miyamoto DT, Efstathiou JA. Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol 2019;76:69-70: Towards Biomarker-Informed Management of Muscle-Invasive Bladder Cancer. Eur Urol. 2019 07; 76(1):71-72. PMID: 30910345.
    Citations: 1     Fields:    Translation:Humans
  21. Mitra D, Horick NK, Brackett DG, Mouw KW, Hornick JL, Ferrone S, Hong TS, Mamon H, Clark JW, Parikh AR, Allen JN, Ryan DP, Ting DT, Deshpande V, Wo JY. High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy. Oncologist. 2019 06; 24(6):e275-e283. PMID: 30755500.
    Citations: 2     Fields:    Translation:Humans
  22. Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. Eur Urol. 2019 07; 76(1):59-68. PMID: 30712971.
    Citations: 17     Fields:    Translation:HumansCells
  23. King MT, Yang DD, Muralidhar V, Mahal B, Butler S, Devlin PM, Lee LJ, Mouw KW, Martin NM, D'Amico AV, Nguyen PL, Orio PF. A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy. 2019 Mar - Apr; 18(2):186-191. PMID: 30638912.
    Citations: 4     Fields:    Translation:Humans
  24. Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM, Preston M, Dong F, Bellmunt J, Mouw KW, Choueiri TK, Sonpavde G, Kwiatkowski DJ. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. Clin Cancer Res. 2019 04 15; 25(8):2458-2470. PMID: 30593515.
    Citations: 6     Fields:    Translation:Humans
  25. Mouw KW, Beck TF, Keen JC, Dicker AP. Assessing the Training and Research Environment for Genomics, Bioinformatics, and Immunology in Radiation Oncology. JCO Clin Cancer Inform. 2018 12; 2:1-9. PMID: 30652612.
    Citations: 3     Fields:    Translation:Humans
  26. Miyamoto DT, Mouw KW, Feng FY, Shipley WU, Efstathiou JA. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncol. 2018 12; 19(12):e683-e695. PMID: 30507435.
    Citations: 9     Fields:    Translation:HumansAnimals
  27. Brody Y, Kimmerling RJ, Maruvka YE, Benjamin D, Elacqua JJ, Haradhvala NJ, Kim J, Mouw KW, Frangaj K, Koren A, Getz G, Manalis SR, Blainey PC. Quantification of somatic mutation flow across individual cell division events by lineage sequencing. Genome Res. 2018 12; 28(12):1901-1918. PMID: 30459213.
    Citations: 2     Fields:    Translation:HumansCells
  28. Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 11 01; 128(11):5185. PMID: 30382943.
    Citations: 6     Fields:    
  29. Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL. Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. Eur Urol. 2019 01; 75(1):35-41. PMID: 30554605.
    Citations: 1     Fields:    Translation:Humans
  30. Yang DD, Muralidhar V, Mahal BA, Beard CJ, Mouw KW, Martin NE, Orio PF, King MT, Nguyen PL. Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. Am J Clin Oncol. 2018 10; 41(10):953-959. PMID: 29045266.
    Citations:    Fields:    Translation:Humans
  31. Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 10 01; 128(10):4441-4453. PMID: 30179225.
    Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
  32. Mouw KW. Toward Biomarker-Informed Trimodality Therapy (TMT) Approaches for Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2018 12 01; 102(5):1417-1419. PMID: 30103024.
    Citations:    Fields:    Translation:Humans
  33. Li Q, Damish AW, Frazier Z, Liu D, Reznichenko E, Kamburov A, Bell A, Zhao H, Jordan EJ, Gao SP, Ma J, Abbosh PH, Bellmunt J, Plimack ER, Lazaro JB, Solit DB, Bajorin D, Rosenberg JE, D'Andrea AD, Riaz N, Van Allen EM, Iyer G, Mouw KW. ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2019 02 01; 25(3):977-988. PMID: 29980530.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  34. Kamran SC, Mouw KW. Applying Precision Oncology Principles in Radiation Oncology. JCO Precis Oncol. 2018; 2. PMID: 32914000.
  35. Haradhvala NJ, Kim J, Maruvka YE, Polak P, Rosebrock D, Livitz D, Hess JM, Leshchiner I, Kamburov A, Mouw KW, Lawrence MS, Getz G. Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. Nat Commun. 2018 05 01; 9(1):1746. PMID: 29717118.
    Citations: 21     Fields:    Translation:HumansCells
  36. Mouw KW, D'Andrea AD. DNA Repair Deficiency and Immunotherapy Response. J Clin Oncol. 2018 06 10; 36(17):1710-1713. PMID: 29683789.
    Citations: 2     Fields:    Translation:Humans
  37. Mouw KW, Konstantinopoulos PA. From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation. Br J Cancer. 2018 04; 118(7):933-935. PMID: 29531322.
    Citations: 8     Fields:    
  38. Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF, Choueiri TK, Taplin ME, Trinh QD, Feng FY, Nguyen PL. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol. 2018 08; 74(2):146-154. PMID: 29478736.
    Citations: 7     Fields:    Translation:Humans
  39. King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D'Amico AV, Nguyen PL, Orio PF. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urol Oncol. 2018 04; 36(4):157.e15-157.e20. PMID: 29276060.
    Citations:    Fields:    Translation:Humans
  40. Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo MY, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, Chen DYT, Alpaugh RK, Hoffman-Censits J, Garraway LA, Getz G, Carter SL, Bellmunt J, Plimack ER, Rosenberg JE, Van Allen EM. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017 12 19; 8(1):2193. PMID: 29259186.
    Citations: 15     Fields:    Translation:HumansCells
  41. Skamene S, Agarwal I, Makar M, Krishnan M, Spektor A, Hertan L, Mouw KW, Taylor A, Noveroske Philbrick S, Balboni T. Impact of a dedicated palliative radiation oncology service on the use of single fraction and hypofractionated radiation therapy among patients with bone metastases. Ann Palliat Med. 2018 Apr; 7(2):186-191. PMID: 29307209.
    Citations: 2     Fields:    Translation:Humans
  42. Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. Clin Genitourin Cancer. 2018 06; 16(3):226-234. PMID: 29196209.
    Citations: 2     Fields:    Translation:Humans
  43. Maruvka YE, Mouw KW, Karlic R, Parasuraman P, Kamburov A, Polak P, Haradhvala NJ, Hess JM, Rheinbay E, Brody Y, Koren A, Braunstein LZ, D'Andrea A, Lawrence MS, Bass A, Bernards A, Michor F, Getz G. Analysis of somatic microsatellite indels identifies driver events in human tumors. Nat Biotechnol. 2017 Oct; 35(10):951-959. PMID: 28892075.
    Citations: 16     Fields:    Translation:HumansCells
  44. Yang DD, Mahal BA, Muralidhar V, Boldbaatar N, Labe SA, Nezolosky MD, Vastola ME, Beard CJ, Martin NE, Mouw KW, Orio PF, King MT, Nguyen PL. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. Cancer. 2017 Dec 15; 123(24):4832-4840. PMID: 28832984.
    Citations: 1     Fields:    Translation:Humans
  45. Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A, Maruvka YE, Leshchiner I, Lander ES, Golub TR, Zick A, Orthwein A, Lawrence MS, Batra RN, Caldas C, Haber DA, Laird PW, Shen H, Ellisen LW, D'Andrea AD, Chanock SJ, Foulkes WD, Getz G. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017 Oct; 49(10):1476-1486. PMID: 28825726.
    Citations: 68     Fields:    Translation:HumansCells
  46. Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF, King MT. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):904-911. PMID: 29063853.
    Citations: 1     Fields:    Translation:Humans
  47. Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov. 2017 07; 7(7):675-693. PMID: 28630051.
    Citations: 85     Fields:    Translation:HumansCells
  48. Mouw KW. DNA Repair Pathway Alterations in Bladder Cancer. Cancers (Basel). 2017 Mar 27; 9(4). PMID: 28346378.
    Citations: 6     
  49. Mouw KW, Yeap BY, Caruso P, Fay A, Misra M, Sethi RV, MacDonald SM, Chen YL, Tarbell NJ, Yock TI, Freitag SK, Munzenrider JE, Grabowski E, Katz M, Kuhlthau K, DeCastro D, Heidary G, Ciralsky J, Mukai S, Shih HA. Analysis of patient outcomes following proton radiation therapy for retinoblastoma. Adv Radiat Oncol. 2017 Jan-Mar; 2(1):44-52. PMID: 28607957.
  50. Mouw KW, D'Amico AV. Post-Prostatectomy Radiation Therapy: Balancing Disease Control and Functional Outcomes. J Urol. 2017 03; 197(3 Pt 1):541-542. PMID: 27993664.
    Citations:    Fields:    Translation:Humans
  51. Mouw KW, Cleary JM, Reardon B, Pike J, Braunstein LZ, Kim J, Amin-Mansour A, Miao D, Damish A, Chin J, Ott PA, Fuchs CS, Martin NE, Getz G, Carter S, Mamon HJ, Hornick JL, Van Allen EM, D'Andrea AD. Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. Clin Cancer Res. 2017 Jun 15; 23(12):3214-3222. PMID: 27852700.
    Citations: 11     Fields:    Translation:Humans
  52. Kim J, Mouw KW, Polak P, Braunstein LZ, Kamburov A, Kwiatkowski DJ, Rosenberg JE, Van Allen EM, D'Andrea A, Getz G. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016 06; 48(6):600-606. PMID: 27111033.
    Citations: 71     Fields:    Translation:HumansAnimalsCells
  53. Mouw KW, D'Andrea AD, Konstantinopoulos PA. Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers. Oncoscience. 2015; 2(12):942-3. PMID: 26909362.
    Citations: 2     
  54. Ceccaldi R, O'Connor KW, Mouw KW, Li AY, Matulonis UA, D'Andrea AD, Konstantinopoulos PA. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res. 2015 Feb 15; 75(4):628-34. PMID: 25634215.
    Citations: 30     Fields:    Translation:HumansCells
  55. Mouw KW, Sethi RV, Yeap BY, MacDonald SM, Chen YL, Tarbell NJ, Yock TI, Munzenrider JE, Adams J, Grabowski E, Mukai S, Shih HA. Proton radiation therapy for the treatment of retinoblastoma. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):863-9. PMID: 25227498.
    Citations: 6     Fields:    Translation:Humans
  56. Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, Bahl S, Gupta N, Farlow D, Qu A, Signoretti S, Barletta JA, Reuter V, Boehm J, Lawrence M, Getz G, Kantoff P, Bochner BH, Choueiri TK, Bajorin DF, Solit DB, Gabriel S, D'Andrea A, Garraway LA, Rosenberg JE. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014 Oct; 4(10):1140-53. PMID: 25096233.
    Citations: 114     Fields:    Translation:HumansCells
  57. Damato AL, Townamchai K, Albert M, Bair RJ, Cormack RA, Jang J, Kovacs A, Lee LJ, Mak KS, Mirabeau-Beale KL, Mouw KW, Phillips JG, Pretz JL, Russo AL, Lewis JH, Viswanathan AN. Dosimetric consequences of interobserver variability in delineating the organs at risk in gynecologic interstitial brachytherapy. Int J Radiat Oncol Biol Phys. 2014 Jul 01; 89(3):674-81. PMID: 24803035.
    Citations: 3     Fields:    Translation:Humans
  58. Mouw KW, D'Andrea AD. Crosstalk between the nucleotide excision repair and Fanconi anemia/BRCA pathways. DNA Repair (Amst). 2014 Jul; 19:130-4. PMID: 24768451.
    Citations: 13     Fields:    Translation:HumansCells
  59. Sethi RV, Shih HA, Yeap BY, Mouw KW, Petersen R, Kim DY, Munzenrider JE, Grabowski E, Rodriguez-Galindo C, Yock TI, Tarbell NJ, Marcus KJ, Mukai S, MacDonald SM. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer. 2014 Jan 01; 120(1):126-33. PMID: 24122173.
    Citations: 32     Fields:    Translation:Humans
  60. Keenholtz RA, Mouw KW, Boocock MR, Li NS, Piccirilli JA, Rice PA. Arginine as a general acid catalyst in serine recombinase-mediated DNA cleavage. J Biol Chem. 2013 Oct 04; 288(40):29206-14. PMID: 23970547.
    Citations: 9     Fields:    Translation:Cells
  61. Mouw KW, Harris JR. Hypofractionation in the era of modulated radiotherapy (RT). Breast. 2013 Aug; 22 Suppl 2:S129-36. PMID: 24074773.
    Citations: 3     Fields:    Translation:Humans
  62. Mouw KW, Trofimov A, Zietman AL, Efstathiou JA. Clinical controversies: proton therapy for prostate cancer. Semin Radiat Oncol. 2013 Apr; 23(2):109-14. PMID: 23473687.
    Citations: 2     Fields:    Translation:Humans
  63. Mouw KW, Harris JR. Irradiation in early-stage breast cancer: conventional whole-breast, accelerated partial-breast, and accelerated whole-breast strategies compared. Oncology (Williston Park). 2012 Sep; 26(9):820-30. PMID: 23061336.
    Citations: 1     Fields:    Translation:Humans
  64. Mouw KW, Solanki AA, Stenson KM, Witt ME, Blair EA, Cohen EEW, Vokes EE, List M, Haraf DJ, Salama JK. Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. Oral Oncol. 2012 Oct; 48(10):1025-1030. PMID: 22621836.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  65. Mouw KW, Haraf DJ, Stenson KM, Cohen EE, Xi X, Witt ME, List M, Blair EA, Vokes EE, Salama JK. Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2010 Dec; 136(12):1226-34. PMID: 21173372.
    Citations: 6     Fields:    Translation:Humans
  66. Mouw KW, Steiner AM, Ghirlando R, Li NS, Rowland SJ, Boocock MR, Stark WM, Piccirilli JA, Rice PA. Sin resolvase catalytic activity and oligomerization state are tightly coupled. J Mol Biol. 2010 Nov 19; 404(1):16-33. PMID: 20868695.
    Citations: 10     Fields:    Translation:Cells
  67. Rice PA, Mouw KW, Montaño SP, Boocock MR, Rowland SJ, Stark WM. Orchestrating serine resolvases. Biochem Soc Trans. 2010 Apr; 38(2):384-7. PMID: 20298188.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  68. Rowland SJ, Boocock MR, McPherson AL, Mouw KW, Rice PA, Stark WM. Regulatory mutations in Sin recombinase support a structure-based model of the synaptosome. Mol Microbiol. 2009 Oct; 74(2):282-98. PMID: 19508283.
    Citations: 17     Fields:    Translation:Cells
  69. Mouw KW, Rowland SJ, Gajjar MM, Boocock MR, Stark WM, Rice PA. Architecture of a serine recombinase-DNA regulatory complex. Mol Cell. 2008 Apr 25; 30(2):145-55. PMID: 18439894.
    Citations: 30     Fields:    Translation:Cells
  70. Mouw KW, Rice PA. Shaping the Borrelia burgdorferi genome: crystal structure and binding properties of the DNA-bending protein Hbb. Mol Microbiol. 2007 Mar; 63(5):1319-30. PMID: 17244195.
    Citations: 27     Fields:    Translation:Cells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mouw's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (255)
Co-Authors (114)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.